Abstract
The molecular signature in patients with systemic sclerosis (SSc)-associated pulmonary arterial hypertension (SSc-PAH) relative to idiopathic pulmonary arterial hypertension (IPAH) remain unclear. We hypothesize that patients with SSc-PAH exhibit unfavorable bioactive metabolite derangements compared to IPAH that contribute to their poor prognosis and limited response to therapy. We sought to determine whether circulating bioactive metabolites are differentially altered in SSc-PAH versus IPAH.
Plasma biosamples from 415 patients with SSc-PAH (cases) and 1115 patients with IPAH (controls) were included in the study. Over 700 bioactive metabolites were assayed in plasma samples from independent discovery and validation cohorts using liquid chromatography - mass spectrometry (LC-MS) based approaches. Regression analyses were used to identify metabolites which exhibited differential levels between SSc-PAH and IPAH and associated with disease severity.
From among hundreds of circulating bioactive molecules, twelve metabolites were found to distinguish between SSc-PAH and IPAH, as well as associate with PAH disease severity. SSc-PAH patients had increased levels of fatty acid metabolites including lignoceric acid and nervonic acid, as well as kynurenine, polyamines, eicosanoids/oxylipins and sex hormone metabolites relative to IPAH. In conclusion, SSc-PAH patients are characterized by an unfavorable bioactive metabolic profile that may explain the poor and limited response to therapy. These data provide important metabolic insights into the pathogenesis of SSc-PAH.
Take Home Message Among patients with PAH, those with SSc-PAH suffer disproportionately worse outcomes and disease course. This study represents the most comprehensive analysis of bioactive metabolites profiling comparing two subgroups of PAH. The findings shed light on key differences between SSc-PAH and IPAH that provide important metabolic insight into the disease pathogenesis.
Competing Interest Statement
Disclosures: S.Y.C. has served as a consultant United Therapeutics; S.Y.C. has held research grants from Actelion and Pfizer. S.Y.C. is a director, officer, and shareholder of Synhale Therapeutics. S.Y.C. has submitted patent applications regarding metabolism in pulmonary hypertension. NHK has served as consultant for Bayer, Janssen, Merck, United Therapeutics and has received lecture fees for Bayer, Janssen. NHK has received research support from Acceleron, Eiger, Gossamer Bio, Lung Biotechnology, SoniVie.
Funding Statement
This work was supported by National Institutes of Health (NIH) grants S10OD020025 and R01ES027595 to M. Jain; K01DK116917 to J.D. Watrous; R01 HL124021, HL105333 to W. Nichols; R01 HL136603 to A. Desai; P01 HL108800 and R01 HL142720 to A.R. Hemnes; HL 122596, HL 138437, and UH2/UH3 TR002073 to S.Y. Chan; R01-HL134168, R01-HL143227, R01-HL142983, and U54-AG065141 to SC. A. Malhotra is funded by NIH. S.Y. Chan was also supported by the American Heart Association Established Investigator Award 18EIA33900027. M. Alotaibi was supported by a postdoctoral fellowship award from the Chest Foundation. A. Malhotra reports income related to medical education from Livanova, Equillium and Corvus. ResMed provided a philanthropic donation to UCSD. K. Kerr received university grant money from Bayer and serve as a consultant for Actelion.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Written informed consent was obtained from participants under a protocol approved by the institutional review board at Cincinnati Children's Hospital Medical Center as well as those at each of the participating centers in the PAH biobank and Vanderbilt Medical center. Written informed consent for publication was obtained at enrollment.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of interest statement: None of the authors have any potential conflicts of interest relative to the study. This work was supported by National Institutes of Health (NIH) grants S10OD020025 and R01ES027595 to M. Jain; K01DK116917 to J.D. Watrous; R01 HL124021, HL105333 to W. Nichols; R01 HL136603 to A. Desai; P01 HL108800 and R01 HL142720 to A.R. Hemnes; HL 122596, HL 138437, and UH2/UH3 TR002073 to S.Y. Chan; R01- HL134168, R01-HL143227, R01-HL142983, and U54-AG065141 to SC. A. Malhotra is funded by NIH. S.Y. Chan was also supported by the American Heart Association Established Investigator Award 18EIA33900027. M. Alotaibi was supported by a postdoctoral fellowship award from the Chest Foundation. A. Malhotra reports income related to medical education from Livanova, Equillium and Corvus. ResMed provided a philanthropic donation to UCSD. K. Kerr received university grant money from Bayer and serve as a consultant for Actelion.
Data Availability
all data referred to in the manuscript is available in the manuscript and supplementary materials.
Abbreviations list
- BMI
- Body mass index
- EpETE
- Epoxyeicosatetraenoic acid
- FAHFA
- Fatty acid ester of hydroxyl fatty acid
- HETE
- Hydroxyeicosanoid
- IPAH
- Idiopathic pulmonary arterial hypertension
- LC-MS
- Liquid chromatography - mass spectrometry
- mRAP
- Mean right atrial pressure
- MRS
- Metabolite risk score
- MUFA
- Monounsaturated unsaturated fatty acids
- PAH
- Pulmonary arterial hypertension
- PVR
- Pulmonary vascular resistance
- RHC
- Right heart catheterization
- SMWD
- 6-minute walk distance
- SSc
- Systemic sclerosis
- SSc-PAH
- Systemic sclerosis associated pulmonary arterial hypertension
- VLCSFA
- Very long chain saturated fatty acids
- WHO FC
- World Health Organization functional class
